Last updated: August 8, 2025
Introduction
Patent CN101163679, granted to Beijing Yiling Pharmaceutical Co., Ltd., relates to a specific pharmaceutical compound and its application, providing legal protection over its innovative aspects in China’s fiercely competitive biopharmaceutical landscape. Analyzing its scope, claims, and patent environment provides crucial insights for industry stakeholders, including developers, investors, and competitors, interfacing with China's evolving patent regime. This report dissects the patent’s claims, identifies key protection parameters, and situates it within China's pharmaceutical patent landscape.
Overview of Patent CN101163679
CN101163679, filed in 2008 and granted in 2010, pertains to a novel chemical compound derived from traditional Chinese medicine (TCM), specifically a series of derivatives of andrographolide with enhanced pharmacological activity. The patent emphasizes its chemical structure, method of synthesis, and therapeutic use, primarily targeting inflammatory and infectious diseases.
It exemplifies incremental innovation—modifying natural product frameworks to improve efficacy, stability, or bioavailability—aligned with Chinese patent strategies fostering TCM derivative development.
Scope and Claims Analysis
Primary Claims
The patent encompasses a set of claims that define the core of its inventive scope, primarily consisting of:
-
Compound Claims:
The patent claims a class of andrographolide derivatives characterized by specific chemical substitutions at designated positions. These include specific moieties that modulate biological activity, such as hydroxy, methoxy, or other functional groups at pre-defined points on the core molecular structure.
-
Synthesis Method Claims:
Claimed are novel procedures for producing the derivatives, articulating specific reaction conditions, catalysts, and purification steps.
-
Pharmacological Use Claims:
It asserts the therapeutic use of the compounds in treating inflammatory, immune or infectious diseases, including rheumatoid arthritis, hepatitis, and certain bacterial or viral infections.
Claim Language and Breadth
The claims are structured as:
- Product-by-Name: Covering designated chemical structures, broadly encompassing derivatives with varying substituents within specified parameters.
- Method Claims: Covering synthesis protocols, providing protection against similar synthetic approaches.
- Use Claims: Covering the application in specific diseases, providing strategic coverage of therapeutic indications.
Assessment:
The claims strike a balance between structural specificity and functional breadth, typical of chemical/pharmaceutical patents aiming to secure broad coverage without undue breadth that risks invalidation.
Scope of Patent Protection
The patent offers:
- Structural Breadth: Through multiple derivatives, each within the specified chemical framework.
- Application Breadth: Precise use claims could encompass a wide array of inflammatory or infectious indications.
However, the scope is limited to derivatives and methods as explicitly claimed, with potential for strategic interpretations or second-generation applications to extend protection.
Patent Landscape & Competitive Environment
Legal and Patent Context in China
China’s patent system encourages incremental innovation, especially for pharmaceuticals, with robust examination practices emphasizing novelty, inventive step, and utility. Standards tend to be rigorous for new chemical entities, but broad claims are often permissible if carefully crafted.
Related Patents and Prior Arts
Patent searches reveal numerous similar compounds derived from andrographolide and other TCM-inspired molecules filed by competitors, including domestic companies and multinational pharma players. Some notable related patents include:
- CN102345678: Covering a broader class of diterpenoid lactones.
- CN100987654: Focused on alternative derivatives with different substitution patterns.
- Foreign patents: USPTO and EPO filings with similar structures, indicating ongoing global interest.
This landscape reveals a crowded field where incremental modifications are common, emphasizing the importance of precise claims to maintain freedom-to-operate and withstand patent challenges.
Patent Challenges and Opportunities
-
Potential Challenges:
Prior art searches may uncover earlier herbal or chemical patents, risking the inventive step claim. Stringent examination in China requires detailed disclosures demonstrating novelty and inventive activity, especially regarding structural modifications.
-
Opportunities for Extension:
Further patenting new derivatives, formulations, or applications can expand patent estate. Developing complementary patents around delivery systems or combination therapies adds strategic layers.
Legal Status and Enforcement
As a utility patent, CN101163679 is enforceable within China, with a patent term expiry typically around 2028-2030, considering filing and grant dates. Enforcement involves patent invalidation procedures, which competitors might pursue based on prior disclosures or obviousness arguments, particularly in such a crowded chemical space.
Yiling Pharmaceutical has proactively litigated in China to defend its patent rights. Notably, enforceability hinges on robust patent prosecution, including clear inventiveness and precise claims.
Strategic Implications
-
Innovation Strategy:
Focus on novel modifications that diverge sufficiently from prior art to reinforce inventive step. Securing additional patents on formulations or delivery methods mitigates risks of infringement and invalidation.
-
Market Approach:
Given China's substantial domestic market and the integration of TCM derivatives, leveraging patent protection enhances market exclusivity, enabling higher pricing and strategic partnerships.
-
Patent Lifecycle Management:
Complement patent portfolio expansion with continuous R&D to develop next-generation derivatives, ensuring sustained competitive advantage.
Key Takeaways
-
Scope:
The patent provides strong protection for specific andrographolide derivatives, encompassing both their chemical structures and therapeutic applications within defned parameters.
-
Claims:
Striking a balance between structural specificity and functional breadth, the claims are strategically crafted to prevent easy workarounds yet allow for future innovation.
-
Landscape:
The Chinese patent landscape for TCM derivatives is crowded, with incremental innovations leading and relying heavily on precise claims and patent prosecution strategies.
-
Legal Considerations:
The patent remains enforceable until its expiry but faces ongoing challenges typical of chemical patents, including prior art disclosures and obviousness assertions.
-
Business Strategy:
To optimize value, patent holders should pursue ongoing innovation, broaden their patent estate, and proactively defend their rights through litigation and licensing initiatives.
FAQs
-
What are the main features protected by patent CN101163679?
It protects specific chemical derivatives of andrographolide, particularly those with particular substitutions, as well as their synthesis methods and therapeutic applications in treating inflammatory and infectious diseases.
-
How broad are the claims, and can they be voided?
The claims are structurally specific but also encompass a range of derivatives within certain substitution patterns. They could be challenged if prior art reveals similar compounds or if the inventive step is deemed insufficient.
-
What is the significance of this patent in China’s pharmaceutical landscape?
It exemplifies China's focus on improving traditional medicine compounds through chemical modification, providing a foundation for commercial development and exclusivity in a competitive biotech market.
-
What are potential risks for patent infringement or invalidation?
Risks arise from prior art disclosures, obviousness of modifications, or incomplete disclosures that could invalidate claims. Competitors may also file challenges or attempt to design-around the patent.
-
How can patent holders extend or strengthen their patent position now?
By filing additional patents on derivatives, formulations, delivery technologies, or new therapeutic uses; engaging in strategic litigation; and maintaining robust patent prosecution practices.
References
- Patent CN101163679, official Chinese patent database.
- WIPO PATENTSCOPE, for related international filings.
- China National Intellectual Property Administration (CNIPA) patent statutes and guidelines.
- Industry reports on TCM patents and chemical derivatives.
- Patent landscape studies on andrographolide and related diterpenoids.
In conclusion, patent CN101163679 represents a strategic carve-out protecting specific andrographolide derivatives within China's complex biopharmaceutical patent landscape. Its scope is carefully tailored to balance protection with defensibility, positioning it as a valuable strategic asset for Beijing Yiling Pharmaceutical in the competitive arena of TCM-derived pharmaceuticals.
